|1.||Lohmander, L S: 5 articles (05/2012 - 02/2006)|
|2.||Struglics, A: 4 articles (05/2012 - 02/2006)|
|3.||Larsson, S: 4 articles (05/2012 - 02/2006)|
|4.||Lohmander, L Stefan: 3 articles (12/2012 - 01/2009)|
|5.||Struglics, André: 3 articles (12/2012 - 01/2009)|
|6.||Arner, Elizabeth C: 3 articles (01/2008 - 02/2002)|
|7.||Tortorella, Micky D: 3 articles (01/2008 - 02/2002)|
|8.||Caterson, B: 3 articles (01/2008 - 08/2000)|
|9.||Sandy, J D: 3 articles (07/2007 - 02/2000)|
|10.||Pratta, M A: 3 articles (07/2006 - 06/2001)|
09/01/2010 - "The short duration of the model combined with the mechanistic biomarker readout makes it very useful for the initial in vivo screening of aggrecanase inhibitors prior to testing them in time and resource-intensive disease models of osteoarthritis (OA)."
01/01/2016 - "These data demonstrate that the antibody is specific to ADAMTS4 and ADAMTS5 and inhibits their aggrecanase activity at molecular and cellular levels, and suggest that this antibody may be useful for treatment of pathological conditions such as osteoarthritis. "
04/01/2013 - "For this reason, considerable effort has been put on the discovery and development of aggrecanase inhibitors able to slow down or halt the progression of osteoarthritis. "
02/01/2008 - "Given the recent characterization of ADAMTS-5 as the main aggrecanase of cartilage destruction in mouse models, we explored whether genetic variation and, in particular, putative damaging polymorphisms in the ADAMTS-5 gene modify susceptibility to osteoarthritis (OA). "
02/01/2008 - "Genetic variation including nonsynonymous polymorphisms of a major aggrecanase, ADAMTS-5, in susceptibility to osteoarthritis."
11/01/2000 - "Catabolism by aggrecanase activities induced in rat chondrosarcoma cells, porcine chondrocytes, and by human recombinant ADAMTS4 showed a gradually decreasing catabolism of progressively shortened, N-terminal deletion mutants of the substrate rAgg1mut. "
10/01/2000 - "Kinetic analysis of the products present in rat chondrosarcoma cell cultures treated with interleukin-1b showed that the first aggrecanase-mediated cleavages occurred at the four sites within the CS attachment region to generate two stable intermediates, Val(1)-Glu(1459) and Val(1)-Glu(1274). "
08/08/1997 - "(iii) A considerable time period was required to synthesize and/or activate aggrecanase, with considerable differences in that found in rat chondrosarcoma versus bovine chondrocyte culture systems. "
08/08/1997 - "Using this recombinant substrate we developed a novel agarose cell culture system containing either rat chondrosarcoma or bovine chondrocytes that could be used in studies of the biochemical characterization of aggrecanase activities. "
07/01/1998 - "Studies in vitro with retinoic acid-stimulated rat chondrosarcoma cells indicated that the rAgg1mut substrate was cleaved at the 'aggrecanase' site equivalent to Glu373-Ala374 (human aggrecan sequence enumeration) in its interglobular domain sequence segment. "
|3.||Joint Diseases (Joint Disease)
12/01/2012 - "These markers can be used to monitor aggrecanase activity in human joint disease. "
01/01/2009 - "The newly developed ARGS fragment assay can be used to monitor aggrecanase activity in human joint disease and experimental models."
09/01/2004 - "Coincident with aggrecanolysis, aggrecanase activities in articular cartilage may actuate the release of HA and associated hyaladherins, thereby further compromising the integrity of the cartilage matrix during degenerative joint diseases such as osteoarthritis."
09/01/1993 - "Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis."
07/01/2006 - "Because aggrecanase mediates degradation of human articular aggrecan in joint disease, the KS/mAb OA-1 ELISA may serve as a biomarker assay for evaluation of preclinical and clinical samples."
04/01/2013 - "Overall, the results of the present study show that ADAMTS-5/aggrecanase-2 is the main aggrecanase present in laryngeal carcinoma suggesting a critical role for the enzyme in aggrecan degradation and laryngeal tissue destruction during tumor progression."
05/01/2005 - "The aggrecanase inhibitory effect of LMWH might contribute to blocking inflammation and tumor invasion by inhibiting aggrecanase activity and maintaining an intact extracellular matrix barrier."
|5.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
|3.||Tretinoin (Retinoic Acid)
|8.||Interleukin-1 (Interleukin 1)
|10.||Messenger RNA (mRNA)